We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: August 9, 2005
Last Update Posted: October 17, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hospices Civils de Lyon
Recent studies have suggested that arginine-vasopressin could be more effective in the treatment of cardiac arrests. The last published study did not outline obvious improvements in the prognosis of all cardiac arrests but pointed out a possible increased survival rate when arginine-vasopressin is associated with epinephrine. The aim of this study is to compare the efficacy of two successive injections of epinephrine (1 mg) with two successive injections of epinephrine associated with arginine-vasopressin (40 UI) in out-of-hospital cardiac arrests occurring in adult patients. The primary endpoint is the survival rate at hospital admission. The inclusion period lasts 18 months and 2416 patients are planned to be enrolled.

Condition Intervention Phase
Cardiac Arrest Drug: epinephrine (1 mg/1 mL) Drug: arginine-vasopressin (40 UI/2 mL) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Comparison of Epinephrine Associated With Vasopressin vs Epinephrine Alone in the Treatment of Out-of-Hospital Cardiac Arrests

Resource links provided by NLM:

Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • Survival at hospital admission

Secondary Outcome Measures:
  • ROSC (Return of spontaneous circulation) Survival at : H24, Day 28, hospital discharge and one year Neurological status at H24 and hospital discharge.

Estimated Enrollment: 2416
Study Start Date: May 2004

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Out-of-hospital medical cardiac arrest in adult patients.

Exclusion Criteria:

  • Traumatic cardiac arrest
  • Pregnancy
  • Patients younger than 18 years old or older than 85 years old
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00127907

Centre Hospitalier Lyon Sud
Pierre Bénite, France, 69495
Sponsors and Collaborators
Hospices Civils de Lyon
Principal Investigator: Pierre-Yves GUEUGNIAUD, MD Hospices Civils de Lyon
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00127907     History of Changes
Other Study ID Numbers: 2003.329
First Submitted: August 5, 2005
First Posted: August 9, 2005
Last Update Posted: October 17, 2007
Last Verified: October 2007

Keywords provided by Hospices Civils de Lyon:
Out-of-hospital cardiac arrest - Vasopressin - Epinephrine

Additional relevant MeSH terms:
Heart Arrest
Out-of-Hospital Cardiac Arrest
Heart Diseases
Cardiovascular Diseases
Epinephryl borate
Arginine Vasopressin
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents